Date | Time | Source | Headline | Symbol | Company |
08/21/2024 | 1:06PM | iHub Newswire | FeaturedMawson Finland Provides Update on Exploration Activities at Rajapalot | | |
07/20/2004 | 9:02AM | PR Newswire (US) | Forest Laboratories Reports Fiscal First Quarter Earnings of $.60 Per Share | NYSE:FRX | Forest Road Acquisition Corp |
07/20/2004 | 9:02AM | PR Newswire (US) | Forest Laboratories, Inc. Announces Share Repurchase Program | NYSE:FRX | Forest Road Acquisition Corp |
07/13/2004 | 12:38PM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2005 First Quarter Earnings | NYSE:FRX | Forest Road Acquisition Corp |
07/06/2004 | 9:04AM | PR Newswire (US) | Forest Laboratories, Inc. and PAION GmbH Announce Development and Marketing Agreement for Desmoteplase - Novel Investigational T | NYSE:FRX | Forest Road Acquisition Corp |
06/29/2004 | 5:46PM | PR Newswire (US) | Forest Announces Request for Information From New York State Office of the Attorney General | NYSE:FRX | Forest Road Acquisition Corp |
06/25/2004 | 10:11AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for TXN, RAD, MYL, FRX, and GILD | NYSE:FRX | Forest Road Acquisition Corp |
06/24/2004 | 5:12PM | PR Newswire (US) | Forest Discusses Disclosure of Citalopram Clinical Trial Data in Children and Adolescents | NYSE:FRX | Forest Road Acquisition Corp |
06/24/2004 | 5:11PM | PR Newswire (US) | Forest Announces Results of Recently Completed Lexapro(R) Pediatric Depression Clinical Trial | NYSE:FRX | Forest Road Acquisition Corp |
05/24/2004 | 10:44AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for GE, MVL, FRX, WYE, and ONE | NYSE:FRX | Forest Road Acquisition Corp |
05/06/2004 | 7:39PM | PR Newswire (US) | Depressed Patients Showed Improvement with Lexapro(TM) After Failure with Initial SSRI Treatment | NYSE:FRX | Forest Road Acquisition Corp |
05/06/2004 | 6:21PM | PR Newswire (US) | Namenda(TM) (memantine HCl) Provides Functional and Behavioral Benefits in Patients with Moderate to Severe Alzheimer's Disease | NYSE:FRX | Forest Road Acquisition Corp |
04/28/2004 | 10:07AM | PR Newswire (US) | New Data Highlight Positive Effect of Namenda(TM) on Brain Activity in Patients With Mild to Moderate Alzheimer's Disease | NYSE:FRX | Forest Road Acquisition Corp |
04/20/2004 | 10:41AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for LU, SWIR, AMTD, BSX, and FRX | NYSE:FRX | Forest Road Acquisition Corp |
04/20/2004 | 9:04AM | PR Newswire (US) | Forest Laboratories Reports Earnings Per Share of $0.38 for Fiscal Fourth Quarter | NYSE:FRX | Forest Road Acquisition Corp |
04/16/2004 | 3:52PM | PR Newswire (US) | Forest Laboratories Receives Notification of ANDA Filing For a Generic Equivalent of Lexapro(R) | NYSE:FRX | Forest Road Acquisition Corp |
04/14/2004 | 9:25AM | PR Newswire (US) | Forest Laboratories, Inc. Sets Date and Conference Call For Fiscal 2004 Fourth Quarter and Full Year Earnings | NYSE:FRX | Forest Road Acquisition Corp |
03/18/2004 | 4:45PM | PR Newswire (US) | /C O R R E C T I O N -- Forest Laboratories, Inc./ | NYSE:FRX | Forest Road Acquisition Corp |
03/15/2004 | 4:33PM | PR Newswire (US) | Lexapro(R) as Effective as Paxil(R) and Well Tolerated in the Treatment of Generalized Anxiety Disorder | NYSE:FRX | Forest Road Acquisition Corp |
03/15/2004 | 8:30AM | PR Newswire (US) | ChemoCentryx and Forest Laboratories to Collaborate on Development and Commercialization of Novel Oral Rheumatoid Arthritis and | NYSE:FRX | Forest Road Acquisition Corp |
03/08/2004 | 6:30AM | PR Newswire (US) | Cypress Bioscience Inc. (Nasdaq: CYPB) to Present at the SG Cowen 24th Annual Healthcare Conference | NYSE:FRX | Forest Road Acquisition Corp |
02/23/2004 | 5:17PM | PR Newswire (US) | Namenda(TM) Shows Benefit in Behavioral Disturbances Associated With Moderate to Severe Alzheimer's Disease | NYSE:FRX | Forest Road Acquisition Corp |
02/23/2004 | 5:05PM | PR Newswire (US) | Researchers Report Namenda(TM) Provides Significant Benefits as Monotherapy to Patients With Mild to Moderate Alzheimer's Diseas | NYSE:FRX | Forest Road Acquisition Corp |
01/09/2004 | 11:04AM | PR Newswire (US) | Forest Laboratories to Exceed Fiscal 2004 Third Quarter Consensus and Guides Full Year to Top End of Previous Guidance | NYSE:FRX | Forest Road Acquisition Corp |
01/09/2004 | 11:03AM | PR Newswire (US) | Cypress Bioscience, Inc., Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Development and Marketing Agreement for | NYSE:FRX | Forest Road Acquisition Corp |
01/08/2004 | 9:24AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for NT, SCHN, FRX, RMBS, And SEPR | NYSE:FRX | Forest Road Acquisition Corp |
01/07/2004 | 8:00AM | PR Newswire (US) | Namenda(TM) (Memantine HCl) Mild to Moderate Alzheimer's Disease Studies Reported Today Forest Laboratories to Seek Approval for | NYSE:FRX | Forest Road Acquisition Corp |
12/18/2003 | 3:46PM | PR Newswire (US) | Lexapro(TM) Receives FDA Approval for the Treatment of Generalized Anxiety Disorder | NYSE:FRX | Forest Road Acquisition Corp |
12/10/2003 | 1:00PM | PR Newswire (US) | Starting Dose of Lexapro(TM) as Effective as Optimally Dosed Zoloft(R) in the Treatment of Major Depressive Disorder | NYSE:FRX | Forest Road Acquisition Corp |
12/03/2003 | 9:23AM | PR Newswire (US) | MORNING UPDATE: Man Securities Issues Alerts for ORCL, ALTR, ABX, FRX, And ADP | NYSE:FRX | Forest Road Acquisition Corp |